Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
Roche's (RHHBY) 9M20 Sales Affected by COVID-19 Outbreak
by Zacks Equity Research
Roche's (RHHBY) performance in the first nine months gets negatively impacted by coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Roche's Tecentriq + Avastin Gets Positive CHMP Opinion for HCC
by Zacks Equity Research
Roche's (RHHBY) combination of immuno-oncology drug, Tecentriq, and Avastin gets positive CHMP opinion for the treatment of advanced or unresectable HCC.
Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer
by Zacks Equity Research
Exelixis (EXEL) signs a collaboration agreement with private biotech NBE-Therapeutics for developing novel antibody-drug conjugates (ADCS) to address cancer. It also inks a similar deal with Catalent.
Exelixis (EXEL) Down 9.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) submits a supplemental new drug application to the FDA seeking approval of Cabometyx in combination with Opdivo for the treatment of advanced renal cell carcinoma.
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter.
Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 75.00% and 11.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Exelixis (EXEL) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. RGEN: Which Stock Is the Better Value Option?
Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis Starts Study on Cabometyx Combo in Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche's Tecentriq.
Exelixis (EXEL) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol-Myers' (BMY) Q1 Earnings & Sales Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the first quarter on strong performance of Revlimid and Eliquis.
Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the first quarter and maintains annual outlook amid coronavirus.
Exelixis (EXEL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 15.38% and 6.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Exelixis (EXEL) Q1 Earnings Expected to Decline
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXEL or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. RGEN: Which Stock Is the Better Value Option?
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Company News for Apr 21, 2020
by Zacks Equity Research
Companies In The News Are: CYCC, CODX, NBY, EXEL
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?